ALRN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 15:59):

Stats
Today's Volume	85 240.00
Average Volume	63 514.00
Market Cap	80.62M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $-0.170 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.390
ATR14	$0.109 (2.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-28	Von Rickenbach Josef H	Buy	2 725	Stock Option (right to buy)
2024-02-28	Ambros Reinhard J.	Buy	2 725	Stock Option (right to buy)
2024-03-25	Garner Charles	Sell	349 750	Stock Option (right to buy)
2024-03-25	Garner Charles	Sell	25 597	Stock Option (right to buy)
2024-03-05	Windsor James Brian	Buy	2 000	Common Stock

INSIDER POWER
-81.21
Last 95 transactions
Buy: 24 990 503 \| Sell: 1 525 640

Volume Correlation

Long: 0.11 (neutral)

Short: -0.59 (weak negative)

Signal:(47.134) Neutral

Aileron Therapeutics Inc Correlation

10 Most Positive Correlations
TTOO	0.931
DCRC	0.918
BNIXU	0.918
JRJC	0.912
REVB	0.91
AVIR	0.909
IMPL	0.908
IMV	0.908
JFU	0.899
LSXMA	0.899

10 Most Negative Correlations
CSII	-0.934
ATCX	-0.932
PAE	-0.931
MELI	-0.93
KIN	-0.926
NYMTZ	-0.922
SCR	-0.919
PCYG	-0.918
ZIXI	-0.915
HPK	-0.913

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aileron Therapeutics Inc Correlation - Currency/Commodity

-0.73
( moderate negative )

-0.60
( weak negative )

0.00
( neutral )

-0.75
( moderate negative )

0.48
( neutral )

0.65
( weak )

Aileron Therapeutics Inc Financials

Annual	2022
Revenue:	$0
Gross Profit:	$-169 000 (0.00 %)
EPS:	$-5.95

Q3	2023
Revenue:	$0
Gross Profit:	$-12 000.00 (0.00 %)
EPS:	$-0.400

Q2	2023
Revenue:	$0
Gross Profit:	$-12 000.00 (0.00 %)
EPS:	$-0.390

Q1	2023
Revenue:	$0
Gross Profit:	$-43 000.00 (0.00 %)
EPS:	$-1.000

Financial Reports:

No articles found.

Aileron Therapeutics Inc

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.